Orchard Therapeutics Ltd - Company Profile
Powered by 
All the sales intelligence you need on Orchard Therapeutics Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Orchard Therapeutics Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Orchard Therapeutics Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Orchard Therapeutics Ltd (Orchard Therapeutics), a subsidiary of Kyowa Kirin Co Ltd, is a biotechnology company that develops gene therapies for rare inherited diseases, including immunological disorders, neurometabolic and neurodegenerative disorders. The company leads product atidarsagene autotemcel, for the treatment of metachromatic leukodystrophy. Its pipeline products include OTL-203 for mucopolysaccharidosis type I; OTL-201, which treats mucopolysaccharidosis type IIIA; OTL-204 targets frontotemporal dementia; and OTL-104 for the treatment of Crohn’s disease. Orchard Therapeutics markets its products under the Libmeldy and Lenmeldy brand names. The company operates in France, Italy, Germany, the UK, the US, Switzerland, Sweden, and the Netherlands. Orchard Therapeutics is headquartered in London, England, the UK.
Headquarters
United Kingdom
Address
3rd Floor, 245 Hammersmith Road, London, England, W68PW
Website
www.orchard-tx.com
Telephone
44 203 8088286
No of Employees
163
Industry
Pharmaceuticals and Healthcare
Revenue (2023)
$19.8M
Orchard Therapeutics Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Atidarsagene Autotemcel: Metachromatic Leukodystrophy (MLD) | Libmeldy |
| Pipeline | Lenmeldy |
| Neurometabolic and Neurodegenerative Disorders: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In February, the company entered into a contract with the Spanish National Health System for reimbursed access to Libmeldy for all MLD patients in the country who fall within the scope of the European marketing authorization. |
| 2024 | Contracts/Agreements | In October, the company entered into partnership with Erkim Pharmaceuticals to broaden access to libmeldy for eligible patients in Turkey and Certain Eurasian Countries. |
| 2024 | Contracts/Agreements | In January, the company entered into partnership with Beneluxa Consortium to enable reimbursed access to libmeldy. |
Competitor Comparison
| Key Parameters | Orchard Therapeutics Ltd | Engitix Ltd | Trio Medicines Ltd | UCB Celltech |
|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | London | London | London | Slough |
| State/Province | England | England | England | England |
| No. of Employees | 163 | 57 | - | 1,326 |
| Entity Type | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Bobby Gaspar, M.D., Ph.D. | Chief Executive Officer | Senior Management | - | - |
| Frank Thomas | Chief Operating Officer; President | Senior Management | - | - |
| Laura Campbell, M.D. | Chief Medical Officer | Senior Management | - | - |
| Fulvio Mavilio, Ph.D | Chief Scientific Officer | Senior Management | - | - |
| Robin Kenselaar | Chief Commercial Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer